Although traditional biomarkers like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have guided clinical decisions (Figure 5), recent advancements in molecular profiling have brought to light promising novel biomarkers for breast cancer diagnoses, prognoses, and treatment response predictions. The gene discussed is ERBB2; the disease is breast carcinoma.